Scalper1 News
Big-cap biotechs Biogen Idec (BIIB) and Celgene (CELG) were headed in opposite directions on the stock market today after JPMorgan upgraded one and downgraded the other. JPMorgan analyst Geoff Meacham lifted his rating on Biogen to overweight from neutral and his price target to 375 from 300. He wrote in a research note that a survey of 50 neurologists had yielded positive opinions on Tecfidera, the oral multiple-sclerosis drug that Biogen Scalper1 News
Scalper1 News